Centre for Immune Regulation and Reproductive Immunology (CIRRI), Department of Clinical Biochemistry, The ReproHealth Research Consortium ZUH, Zealand University Hospital, Department of Clinical Medicine, University of Copenhagen, Denmark.
Division of Maternal-Fetal Medicine, Oregon Health & Sciences University, Portland, OR, USA.
Placenta. 2019 Jan;75:27-33. doi: 10.1016/j.placenta.2018.11.008. Epub 2018 Nov 22.
The pathogenesis of preeclampsia may involve inadequate trophoblast invasion caused by excessive inhibition of uterine natural killer cells (uNK) by extravillous trophoblast cells (EVT). This may be the result of a combination of maternal killer-cell immunoglobin-like receptor (KIR) AA genotype and fetal human leukocyte antigen-C2 (HLA-C2) genotype. A few studies have reported a significantly increased frequency of the maternal KIR AA/fetal HLA-C2 combination in cases of preeclampsia compared to controls.
Study subjects were 259 cases of severe preeclampsia/eclampsia and 259 matched pregnant women without preeclampsia or eclampsia. All pregnancies were singleton pregnancies, and mothers were preferentially primigravidae. Blood samples from women and their newborns were obtained from the Danish National Birth Cohort (DNBC) and the Danish Neonatal Screening Biobank. Significant differences in the frequencies of KIR AA and HLA-C2 between cases and controls were investigated.
No significant difference was observed between cases and controls in the frequency of maternal KIR AA (OR = 0.86, 95%CI = 0.60-1.23, P = 0.41), neither when the fetus carried an HLA-C2 allele (OR = 0.85, 95%CI = 0.52-1.38, P = 0.51), nor when the fetus carried an HLA-C2 allele more than its mother (OR = 0.75, 95%CI = 0.34-1.64, P = 0.47).
The Results show no influence of HLA-C/KIR genetic variation on the risk of severe preeclampsia, contrary to what some previous studies have observed. An explanation could be that severe preeclampsia represents a separate pathological entity compared to mild preeclampsia.
子痫前期的发病机制可能涉及滋养细胞侵袭不足,这是由于绒毛外滋养细胞对子宫自然杀伤细胞(uNK)的过度抑制所致。这可能是由于母体杀伤细胞免疫球蛋白样受体(KIR)AA 基因型和胎儿人类白细胞抗原-C2(HLA-C2)基因型的组合所致。一些研究报道,与对照组相比,子痫前期病例中母体 KIR AA/胎儿 HLA-C2 组合的频率明显升高。
研究对象为 259 例重度子痫前期/子痫病例和 259 例匹配的无子痫前期或子痫的孕妇。所有妊娠均为单胎妊娠,母亲优先为初产妇。从丹麦国家出生队列(DNBC)和丹麦新生儿筛查生物库中获取妇女及其新生儿的血液样本。研究了病例组和对照组中 KIR AA 和 HLA-C2 的频率是否存在显著差异。
病例组和对照组中母体 KIR AA 的频率无显著差异(OR=0.86,95%CI=0.60-1.23,P=0.41),当胎儿携带 HLA-C2 等位基因时(OR=0.85,95%CI=0.52-1.38,P=0.51),当胎儿携带 HLA-C2 等位基因多于其母亲时(OR=0.75,95%CI=0.34-1.64,P=0.47)。
结果表明,HLA-C/KIR 遗传变异对重度子痫前期的风险没有影响,与一些先前的研究观察结果相反。一种解释可能是重度子痫前期与轻度子痫前期相比是一种独立的病理实体。